Wcn24-1868 Assist: a Randomized, Double-blind, Placebo-controlled Crossover Trial of Atrasentan in Patients With Iga Nephropathy (igan) on Sglt2i
Year: 2024
Type: article
Abstract: IgA nephropathy (IgAN) is the leading cause of primary glomerulonephritis and has limited treatment options. Endothelin A (ETA) receptor activation drives increase in proteinuria, kidney inflammation and fibrosis. In interim results of a phase 2, open-label study in patients with IgAN (AFFINITY), atrasentan, a potent and selective ETA antagonist, was well tolerated and resulted in clinically meaningful proteinuria reduction. Meanwhile, in a post-hoc analysis in patients with type 2 diabetes and CKD (SONAR), treatment with sodium glucose cotransporter-2 inhibitors (SGLT2i) and atrasentan resulted in greater reductions in albuminuria compared to atrasentan alone (n=14).
Source: Kidney International Reports
Institutions: University Hospitals of Leicester NHS Trust, Hospital Clínico Universitario de Valencia, The George Institute for Global Health, Prince of Wales Hospital, The George Institute for Global Health, University Malaya Medical Centre, Chinook Therapeutics (United States), University of North Carolina at Chapel Hill, University Medical Center Groningen
Language: English
Subfield: Nephrology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $2,800
OpenAlex ID: W4393851446